SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : JNJ-Super company, Super stock!
JNJ 188.87-0.1%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Lance Bredvold who wrote (471)1/7/2004 9:45:44 AM
From: David Lawrence  Read Replies (1) of 552
 
>With the PE now down around 23, I still feel that is plenty high and would be most comfortable if the price to trailing earnings were about 15 which I regard as ordinary and proper.

It's hard to imagine that absent a total meltdown at Cordis or a market crash. As you pointed out, solid management, diversified profitable business lines, and excellent visibility will be rewarded with an above average relative PE.

Medtronic and Guidant are also expected to re-enter the domestic stent market next year, but they'll be choking on JNJ's and BSX's heel dust. BSX's coated stent market share has already passed JNJ in Europe, which explains the analyst expectations for an equally strong showing in the US. Of course, the patent dispute remains... but who knows when that will be resolved.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News